Bacterial Infections Respiratory, Lung Diseases, Mycobacterium Infections, Tuberculosis, Tuberculosis, Pulmonary
Conditions
Keywords
Anti-Bacterial Agents
Brief summary
This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of \[14C\]BTZ-043 in 4 healthy adult male subjects
Detailed description
A total of 4 evaluable subjects completing all procedures are required. Six (6) subjects will be enrolled in the cohort in order to have 4 evaluable subjects. The study will consist of a screening period (Day -21 to -2), a baseline period (Day -1), a single dose treatment on Day 1 with a minimum of 96 hours (=4 days) post dose in-house observation period (Days -1 up to afternoon Day 5), and a follow-up visit 30 days (±2 days) after the \[14C\]BTZ-043 dose. Subjects will be administered a single 500 mg \[14C\]BTZ-043 dose as drinking suspension. Subjects will be confined to the clinical site for at least 96 hours following drug administration (ie, afternoon of Day 5). During this time, blood, feces, and urine samples for measurement of \[14C\]BTZ-043 and metabolites will be collected. The subjects will be released from the clinic approximately 96 hours to 168 hours after dose administration and upon satisfactory recovery of radioactivity (at least 90%) approved by the Sponsor's scientific advisor after consulation of the Sponsor.
Interventions
DRUG500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043
Single oral administration of 14C-labeled radioactive 500mg BTZ-043
Sponsors
Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institute
Michael Hoelscher
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Sex : male 2. Age : 18 years to 55 years, inclusive, at screening. 3. Body mass index (BMI) : 18.0 to 29.0 kg/m2, inclusive, at screening. 4. Weight : 55 to 90 kg, inclusive, at screening. 5. Status : healthy subjects. 6. Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner, if she is of childbearing potential) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence, in accordance with the lifestyle of the subject, is also acceptable. 7. All prescribed medication must have been stopped at least 30 days prior to admission to the clinical research center. 8. All over-the-counter medications, vitamin preparations (especially vitamin C), other food supplements, and herbal medications (eg, St. John's wort) must have been stopped at least 14 days prior to admission to the clinical research center. An exception is made for paracetamol, which is allowed up to 48 hours prior to study drug administration. 9. No vaccination within 14 days prior to study drug administration. 10. Ability and willingness to abstain from alcohol from 48 hours (2 days) prior to screening and admission to the clinical research center. 11. Ability and willingness to abstain from methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, and energy drinks), grapefruit (juice), corn (whole corn kernels and popcorn), cruciferous vegetables, and bitter oranges from 48 hours (2 days) prior to admission to the clinical research center. 12. Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, ECG, and vital signs, as judged by the Investigator. 13. Willing and able to sign the ICF.
Exclusion criteria
1. Participation in another study with a radiation burden of \>0.1 mSv and ≤1 mSv in the period of 1 year prior to screening; a radiation burden of \>1.1 mSv and ≤2 mSv in the period of 2 years prior to screening; a radiation burden of \>2.1 mSv and ≤3 mSv in the period of 3 years prior to screening, etc. 2. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton \[excluding spinal column\]), or during work within 1 year prior to drug administration. 3. Irregular defecation pattern (less than once per day on average). 4. Employee of PRA, Nuvisan, or the Sponsor. 5. History of relevant drug and/or food allergies. 6. Using tobacco products within 60 days prior to drug administration. 7. History of alcohol abuse or drug addiction (including soft drugs like cannabis products). 8. Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, gamma-hydroxybutyric acid, tricyclic antidepressants, and alcohol) at screening or admission to the clinical research center. 9. Average intake of more than 24 grams of alcohol per day. 10. Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or HIV 1 and 2 antibodies. 11. Participation in a drug study within 30 days prior to drug administration in the current study. Participation in more than 4 drug studies in the 12 months prior to drug administration in the current study. 12. Donation or loss of more than 450 mL of blood within 60 days prior to drug administration. Donation or loss of more than 1.5 liters of blood in the 10 months prior to drug administration in the current study. 13. Significant and/or acute illness within 5 days prior to drug administration that may impact safety assessments, in the opinion of the Investigator. 14. Unwillingness to consume the Food and Drug Administration (FDA)-recommended high-fat breakfast. 15. Unsuitable veins for infusion or blood sampling. 16. Positive nasopharyngeal PCR test for SARS-CoV-2 on Day -1.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Urine Concentrations of BTZ-043 and Main Metabolites | Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total). | Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose. |
| Rates and Routes of Excretion | Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours. | To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043). |
| Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax) | Blood samples for total radioactivity were collected from day 1 until 168 h post dosing | To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated. |
| Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t) | Blood samples for total radioactivity were collected from day 1 until 168 h post dosing | To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated. |
| Pharmacokinetics of Total Radioactivity in Blood (T1/2) | Blood samples for total radioactivity were collected from day 1 until 168 h post dosing | To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated. |
| Pharmacokinetics of Total Radioactivity in Plasma (T1/2) | Blood samples for total radioactivity were collected from day 1 until 168 h post dosing | To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated. |
| Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Day 1 to Day 3 | To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements. |
| Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | Day 1 to Day 3 | To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements. |
| Plasma PK of BTZ-043 and Main Metabolites (t1/2) | Day 1 to Day 3 | To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events | Day -1 to day 32 | To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers. |
Countries
Netherlands
Participant flow
Recruitment details
Screening started on 27th September 2021. The first participant was enrolled on October 8th, 2021. The healthy volunteers were recruited by PRA Health Sciences - Early Development Services in 9728 NZ Groningen
Participants by arm
| Arm | Count |
|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 4 subjects to receive a single oral administration of 14C-labeled radioactive 500mg BTZ-043 containing 3.7 MBq of \[14C\]BTZ-043 | 4 |
| Total | 4 |
Baseline characteristics
| Characteristic | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants |
| Age, Continuous | 22 years STANDARD_DEVIATION 3 |
| BMI | 24.3 kg/m² STANDARD_DEVIATION 4 |
| Height | 177 cm STANDARD_DEVIATION 2 |
| Race/Ethnicity, Customized Race White | 3 Participants |
| Race/Ethnicity, Customized Race White + Black or African American | 1 Participants |
| Region of Enrollment Netherlands | 4 participants |
| Sex/Gender, Customized Male | 4 Participants |
| Weight | 75.7 kg STANDARD_DEVIATION 13 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 4 |
| other Total, other adverse events | 4 / 4 |
| serious Total, serious adverse events | 0 / 4 |
Outcome results
Primary
Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Population: per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t) | AUC-t Plasma | 125000 h*ng eq/mL | Standard Deviation 26900 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t) | AUC-t Blood | 76700 h*ng eq/mL | Standard Deviation 18500 |
Primary
Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Population: per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax) | Cmax Plasma | 8730 ng eq/mL | Standard Deviation 2550 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax) | Cmax Blood | 4970 ng eq/mL | Standard Deviation 1370 |
Primary
Pharmacokinetics of Total Radioactivity in Blood (T1/2)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Population: per protocol. On participant excluded as value was justed unreliable
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Blood (T1/2) | 158 h | Standard Deviation 24.7 |
Primary
Pharmacokinetics of Total Radioactivity in Plasma (T1/2)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Population: per protocol.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Pharmacokinetics of Total Radioactivity in Plasma (T1/2) | 186 h | Standard Deviation 18.9 |
Primary
Plasma PK of BTZ-043 and Main Metabolites (AUC-last)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Population: Per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | AUClast BTZ-043 | 3920 h*ng/mL | Standard Deviation 842 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | AUClast M1 | 2710 h*ng/mL | Standard Deviation 433 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | AUClast M2 | 41000 h*ng/mL | Standard Deviation 6220 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | AUClast M4total | 10300 h*ng/mL | Standard Deviation 3990 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (AUC-last) | AUClast M10 | 505 h*ng/mL | Standard Deviation 199 |
Primary
Plasma PK of BTZ-043 and Main Metabolites (Cmax)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Population: Per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Cmax M4total | 1190 ng/mL | Standard Deviation 455 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Cmax M10 | 30.6 ng/mL | Standard Deviation 6.5 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Cmax BTZ-043 | 1600 ng/mL | Standard Deviation 509 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Cmax M1 | 163 ng/mL | Standard Deviation 27.5 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (Cmax) | Cmax M2 | 5180 ng/mL | Standard Deviation 1310 |
Primary
Plasma PK of BTZ-043 and Main Metabolites (t1/2)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Population: Per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (t1/2) | T1/2 M1 | 8.65 h | Standard Deviation 0 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (t1/2) | T1/2 M4total | 3.83 h | Standard Deviation 0.281 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (t1/2) | T1/2 BTZ-043 | 2.43 h | Standard Deviation 1.01 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (t1/2) | T1/2 M2 | 4.90 h | Standard Deviation 0.591 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Plasma PK of BTZ-043 and Main Metabolites (t1/2) | T1/2 M10 | 18.9 h | Standard Deviation 10.2 |
Primary
Rates and Routes of Excretion
To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043).
Time frame: Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours.
Population: Per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Rates and Routes of Excretion | total drug-related radioactivity in urine | 331 mg eq | Standard Deviation 23.2 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Rates and Routes of Excretion | total drug-related radioactivity in faeces | 162 mg eq | Standard Deviation 23 |
Primary
Urine Concentrations of BTZ-043 and Main Metabolites
Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose.
Time frame: Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total).
Population: Per protocol
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | BTZ-043 (M0) Cumulative Amount Excreted 0 - 24h | 8.83 mg eq | Standard Deviation 4.51 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M1 Cumulative Amount Excreted 0 - 24h | 1.53 mg eq | Standard Deviation 0.518 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M2 Cumulative Amount Excreted 0 - 24h | 53.9 mg eq | Standard Deviation 17.1 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M10 total Cumulative Amount Excreted 0 - 48h | 2.65 mg eq | Standard Deviation 1.45 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-48h | 128 mg eq | Standard Deviation 16.4 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M2 Cumulative Amount Excreted 0 - 48h | 54.7 mg eq | Standard Deviation 17.3 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M4 total Cumulative Amount Excreted 0 - 24h | 59.4 mg eq | Standard Deviation 9.77 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M4 total Cumulative Amount Excreted 0 - 48h | 60.5 mg eq | Standard Deviation 10.2 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | M10 total Cumulative Amount Excreted 0 - 24h | 2.47 mg eq | Standard Deviation 1.33 |
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Urine Concentrations of BTZ-043 and Main Metabolites | Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-24h | 126 mg eq | Standard Deviation 15.7 |
Secondary
Number of Adverse Events
To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers.
Time frame: Day -1 to day 32
Population: Received at least one dose of BTZ-043
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | Number of Adverse Events | 6 Adverse Events |